(NASDAQ: SLNO) Soleno Therapeutics's forecast annual revenue growth rate of 171.23% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 87.6%, and it is also forecast to beat the US market's average forecast revenue growth rate of 11.61%.
Soleno Therapeutics's revenue in 2025 is $32,657,000.On average, 4 Wall Street analysts forecast SLNO's revenue for 2025 to be $7,268,749,171, with the lowest SLNO revenue forecast at $5,820,441,386, and the highest SLNO revenue forecast at $8,450,056,431. On average, 4 Wall Street analysts forecast SLNO's revenue for 2026 to be $20,396,523,004, with the lowest SLNO revenue forecast at $16,307,546,012, and the highest SLNO revenue forecast at $26,838,229,545.
In 2027, SLNO is forecast to generate $35,070,657,164 in revenue, with the lowest revenue forecast at $25,892,779,835 and the highest revenue forecast at $44,248,534,493.